would be larger in cancers with longer median survival postprogression [2] . In addition, the time gain is very large in cancers for which the response rate is used as a surrogate end point such as hematological malignancy [3] .
Second, we are not discussing a surrogate end point for less serious disease like cardiovascular disease [4] , but are discussing a surrogate end point supporting clinical trials of innovative new drugs of high unmet medical need used for treating patients with serious life-threatening diseases. The emphasis is on the importance when a validated surrogate end point of clinical benefits is proven to be useful in such a situation. In the FDA's accelerated approval program, clinical benefit was confirmed in post-approval trials for 26 of the 47 indications. It is 'not only' 26; patients could benefit from earlier availability of the drug with more than half of new indications (26 of 47 indications) [5] .
As Dr Braillon pointed out in the last, validation of surrogate end points is of course important, and decision on the acceptance of surrogate end points must be made strictly. Surrogate end points should carry the risk of error. Apart from this, we do not find exactly equivalent system to FDA's accelerated approval or breakthrough therapy designation in our domestic regulatory environment, there is only a limited place to discuss surrogate end points in Japan [6] .
We understand his approach 'Festina Lente' he quoted, but we would prefer 'never hesitate to do good and make haste to do what is right'. Atypical femur fractures associated with use of bisphosphonates and denosumab
We applaud the authors of the ESMO 2014 Bone and Cancer Guidelines (Annals of Oncology) for a succinct summary of this important aspect of cancer care. Regarding the safety aspects section, we wish to add a rare, potentially serious, and often underappreciated adverse effect of potent antiresorptive therapy (bisphosphonates and denosumab) to those mentioned -atypical subtrochanteric femur fracture (AFF). The ASBMR (American Society of Bone and Mineral Research) has recently revised the case definition of AFF and make mention that 'several radiological and clinical features differ fundamentally from ordinary osteoporotic femur fractures and strongly suggest a distinct pathogenesis' [1] . AFF has been well described in patients treated with bisphosphonates to reduce the risk of osteoporotic fracture, and it may also occur during treatment with denosumab for osteoporosis [1] . In the setting of osteoporosis, risk appears to increase with duration of therapy [2] . In the setting of antiresorptive therapy as indicated to reduce the risk of skeletal related events in patients with malignant bone disease, data on AFF is much more scant [3, 4]. The pathophysiology of AFF is poorly understood and is thought to be related to failure to heal fatigue damage or microcracks resulting in an insufficiency fracture [1] . Clinicians should be aware that this adverse event may present with a prodrome of dull or aching anterior thigh or groin pain and that these fractures are often bilateral. Imaging early in the clinical course may be consistent with a stress reaction along the lateral femur-this may be confused with metastatic disease in our experience. If AFF is suspected, potent antiresorptive therapy should be discontinued and the patient should be referred to an orthopedist given the potential for early changes detected on imaging to progress to complete fracture. Reply to the letter to the editor 'Albumin to globulin ratio, a predictor or a misleader?' by Alkan et al.
We appreciate the letter to the editor by Alkan et al. [1] in response to our recently published article [2]. Alkan et al. bring up some potentially valid points about our study. They suggest rheumatic diseases should have been excluded from the study population, as these conditions are 'important causatives for chronic inflammation.' They also suggest the inclusion of elderly subjects older than 60, comprising 24.2% of the study population, may be misleading to the results, as these subjects are 'prone to malnutrition and also hypoalbuminemia.' In order to address these suggestions, we have investigated the association of low albumin-to-globulin ratio (AGR) with cancer after having further excluded (in addition to the exclusion criteria originally implemented in our study) elderly subjects older than 60, as well as subjects with previous history of major rheumatic diseases, including rheumatic arthritis (ICD-10 M05), systemic lupus erythematosis (M32), ankylosing spondylitis (M45), systemic sclerosis (M34), dermatopolymyositis (M33), other connective tissue disease (M35-M36), as well as Crohn's disease (K50), and ulcerative colitis (K51). The study population thus decreased from 26 974 to 20 695 subjects.
The results are shown in Table 1 . As expected, event numbers have significantly decreased (∼70%) but the overall trend is shown to be apparently intact, with adjusted hazard ratios remaining similar in general throughout all AGR groups.
Overall, the association between low AGR and cancer is a legitimate observation, although its clinical application remains undetermined, deserving elucidation by future studies. 
